{"nctId":"NCT01307046","briefTitle":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","startDateStruct":{"date":"2011-03-29","type":"ACTUAL"},"conditions":["Hypertension"],"count":336,"armGroups":[{"label":"MK-0954A","type":"EXPERIMENTAL","interventionNames":["Drug: MK-0954A","Drug: Placebo to losartan 100 mg","Drug: Placebo to losartan 50 mg"]},{"label":"Losartan","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Losartan","Drug: Placebo to MK-0954A","Drug: Placebo to losartan 50 mg"]}],"interventions":[{"name":"MK-0954A","otherNames":[]},{"name":"Losartan","otherNames":[]},{"name":"Placebo to MK-0954A","otherNames":[]},{"name":"Placebo to losartan 100 mg","otherNames":[]},{"name":"Placebo to losartan 50 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participant has a diagnosis of essential hypertension.\n* Participant is not treated with antihypertensive medication and meets protocol-specified blood pressure criteria.\n* Participant is treated with single antihypertensive medication, and meets protocol-specified blood pressure criteria.\n* Participant is being treated with up to dual oral antihypertensive medications, and will be able to discontinue the prior antihypertensive medication.\n* Participant has no clinically meaningful findings to be disqualified from the study at the discretion of the investigator.\n\nExclusion criteria:\n\n* Regarding hypertension, participant is currently taking \\> 2 antihypertensive medications.\n* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing \"chlortalidone\" medicines)\n* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or a recent history within the last year of drug or alcohol abuse or dependence.\n* Participant is pregnant or breastfeeding or expecting to conceive or has a positive pregnancy test at the screening visit.\n* Participant is currently participating or has participated in a study with an investigational compound (except losartan at any doses) or device within 30 days of signing informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)","description":"Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"0.6"},{"groupId":"OG001","value":"-3.6","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP)","description":"Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","spread":null},{"groupId":"OG001","value":"-5.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event (AE)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"26.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":166},"commonTop":["Nasopharyngitis"]}}}